Sources

12 Total Sources

Johnson & Johnson Lifts 2026 Outlook After $25.31 Billion Q2 Beat

Left56%

Center44%

Johnson & Johnson Beats Q2 Estimates on Tremfya, Darzalex Strength; Raises Full-Year Forecasts

Johnson & Johnson CFO Joseph Wolk on the company's Q2 results

Johnson & Johnson CFO says this drug is outperforming 'almost any launch' in recent memory

Marketscreener.com1d ago

J&J medtech miss overshadows earnings beat | MarketScreener

Investing.com Canada1d ago

Johnson & Johnson Q2 2026 slides: $100B revenue target in sight By Investing.com

pharma.economictimes.indiatimes.com10h ago

Johnson & Johnson Exceeds Q2 Expectations with Strong Pharmaceutical Sales, ETPharma

investorshub.advfn.com16h ago

Johnson & Johnson tops second-quarter forecasts and lifts guidance despite premarket decline (JNJ)

Yahoo Finance1d ago

J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised

signalbloom.ai1d ago

Johnson & Johnson Raises Full-Year Outlook After Topping Q2 Estimates, But Growth Slows - SignalBloom AI

Johnson & Johnson posts Q2 2026 earnings beat on medicines unit strength

J&J medtech miss overshadows earnings beat - AOL

Investing.com1d ago

Johnson & Johnson Q2 2026 slides: $100B revenue target in sight By Investing.com